WHO’s take on remdesivir leads to more confusion over coronavirus drugs

whos take on remdesivir leads to more confusion over coronavirus drugs

Sumary of WHO’s take on remdesivir leads to more confusion over coronavirus drugs:

  • Health officials around the world are clashing over the use of certain drugs for COVID-19, leading to different treatment options for patients depending on where they live..
  • On Friday, a World Health Organization guidelines panel advised against using the antiviral remdesivir for hospitalized patients, saying there no evidence it improves survival or avoids the need for breathing machines..
  • Within the U.S., a federal guidelines panel and some leading medical groups have not endorsed two other therapies the Food and Drug Administration authorized for emergency use — Eli Lilly experimental antibody drug and convalescent plasma, the blood of COVID-19 survivors..
  • Until the National Institutes of Health guidelines endorse a treatment, “I’m really reluctant … to call that standard of care.”.
  • “It not unusual for professional guidelines to disagree with each other, it just that it all under the microscope with COVID-19,”.
  • The WHO guidelines stress that the drug does not save lives, based heavily on a WHO-sponsored study that was larger but much less rigorous than the U.S.-led one that found it had other benefits..
  • Gilead charges $3,120 for a typical treatment course for patients with private insurance and $2,340 for people covered by government health programs in the U.S….

Want to know more click here go to health news source.

From -

Close

Languages